Adaptimmune Therapeutics PLC (ADAP)
0.6366
-0.03
(-4.23%)
USD |
NASDAQ |
Nov 21, 16:00
0.61
-0.03
(-4.18%)
After-Hours: 04:55
Adaptimmune Therapeutics Enterprise Value: 26.67M for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | 26.67M |
| November 20, 2024 | 33.86M |
| November 19, 2024 | 36.44M |
| November 18, 2024 | 16.03M |
| November 15, 2024 | 13.88M |
| November 14, 2024 | 15.05M |
| November 13, 2024 | 60.96M |
| November 12, 2024 | 66.87M |
| November 11, 2024 | 74.59M |
| November 08, 2024 | 67.63M |
| November 07, 2024 | 62.52M |
| November 06, 2024 | 75.46M |
| November 05, 2024 | 76.10M |
| November 04, 2024 | 75.46M |
| November 01, 2024 | 68.38M |
| October 31, 2024 | 49.39M |
| October 30, 2024 | 42.03M |
| October 29, 2024 | 44.00M |
| October 28, 2024 | 52.36M |
| October 25, 2024 | 52.44M |
| October 24, 2024 | 55.64M |
| October 23, 2024 | 64.56M |
| October 22, 2024 | 70.99M |
| October 21, 2024 | 74.52M |
| October 18, 2024 | 79.35M |
| Date | Value |
|---|---|
| October 17, 2024 | 79.04M |
| October 16, 2024 | 86.59M |
| October 15, 2024 | 88.89M |
| October 14, 2024 | 88.66M |
| October 11, 2024 | 86.74M |
| October 10, 2024 | 88.64M |
| October 09, 2024 | 91.37M |
| October 08, 2024 | 96.26M |
| October 07, 2024 | 96.57M |
| October 04, 2024 | 107.06M |
| October 03, 2024 | 92.73M |
| October 02, 2024 | 87.54M |
| October 01, 2024 | 99.48M |
| September 30, 2024 | 106.90M |
| September 27, 2024 | 60.08M |
| September 26, 2024 | 49.80M |
| September 25, 2024 | 45.27M |
| September 24, 2024 | 58.49M |
| September 23, 2024 | 50.08M |
| September 20, 2024 | 64.91M |
| September 19, 2024 | 68.47M |
| September 18, 2024 | 76.14M |
| September 17, 2024 | 78.70M |
| September 16, 2024 | 78.70M |
| September 13, 2024 | 94.04M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-98.43M
Minimum
Mar 15 2022
1.554B
Maximum
Jun 04 2020
242.16M
Average
120.93M
Median
Aug 04 2022
Enterprise Value Benchmarks
| Biodexa Pharmaceuticals PLC | -3.355M |
| NuCana PLC | -11.87M |
| Autolus Therapeutics PLC | 98.72M |
| Bicycle Therapeutics PLC | 508.01M |
| TC BioPharm (Holdings) PLC | -0.927M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -17.62M |
| Revenue (Quarterly) | 40.90M |
| Total Expenses (Quarterly) | 55.58M |
| EPS Diluted (Quarterly) | -0.06 |
| Profit Margin (Quarterly) | -43.07% |
| Earnings Yield | -28.28% |
| Normalized Earnings Yield | -28.28 |